michael dulchin, md p.c.

817 broadway, 5th flr
new york, new york 10003

NYS Entity Status
ACTIVE

NYS Filing Date
MARCH 18, 2013

NYS DOS ID#
4375452

County
NEW YORK

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC PROFESSIONAL CORPORATION

Name History
2013 - MICHAEL DULCHIN, MD P.C.









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Online Portals Challenge WebMD as Patients’ Source for Health Info
    By Jeff Buchanan - Thursday Sep 14, 2017

    Suppose you wake up with a mysterious rash. Or you’ve got back pain, or have come down with a cough unlike any you’ve experienced previously. What’s your first move? Maybe you run a Google search. Maybe you text a doctor or nurse you know. Or maybe you attempt to get through your normal morning routine, […]

    Source: Xconomy New York
  • KKR to Buy WebMD in $2.8 Billion Deal
    Monday Jul 24, 2017

    KKR has reached a deal to buy WebMD Health Corp. for $2.8 billion. The New York-based health-information provider had been running an auction after publicly putting itself in play earlier this year.

    Source: The Wall Street Journal: U.S. Business
  • What Steps Should NY Biotech Take in 2018? Share Your View on Dec. 11
    By Ben Fidler - Monday Nov 20, 2017

    Change takes time. Particularly in the life sciences, where a single drug’s journey from idea to market can consist of more than a decade of small, yet critical steps. For New York, then, aspirations to become a region known for its biotech industry are—and always have been—a long game in which every year and bit […]

    Source: Xconomy New York
  • Acorda Scraps One Parkinson’s Drug, Puts Its Cash Behind Another
    By Frank Vinluan - Monday Nov 20, 2017

    Acorda Therapeutics said Monday that it will stop work on an experimental treatment for Parkinson’s disease, spelling the end for a drug the Ardsley, NY, company added to its pipeline last year in a $363 million deal. The announcement follows the recent emergence of safety problems for the Acorda (NASDAQ: ACOR) drug, tozadenant. Acorda said […]

    Source: Xconomy New York